These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 18230900)

  • 1. Role of the endocannabinoid system in energy balance regulation and obesity.
    Cota D
    Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors.
    Davis SN; Perkins JM
    Endocr Pract; 2007; 13(7):790-804. PubMed ID: 18194939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoid control of food intake and energy balance.
    Di Marzo V; Matias I
    Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The endocannabinoid system].
    Sudano I; Périat D; Noll G
    Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health.
    Cota D
    Diabetes Metab Res Rev; 2007 Oct; 23(7):507-17. PubMed ID: 17683024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications.
    Viveros MP; de Fonseca FR; Bermudez-Silva FJ; McPartland JM
    Endocr Metab Immune Disord Drug Targets; 2008 Sep; 8(3):220-30. PubMed ID: 18782018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Endocannabinoid system and energy metabolism: physiology and pathophysiology].
    Pagotto U; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):74S-82S. PubMed ID: 18773754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
    Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
    Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?
    Horvath TL
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S30-2. PubMed ID: 16570102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.
    Bennetzen MF
    Dan Med Bull; 2011 Apr; 58(4):B4269. PubMed ID: 21466769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system: a promising target for the management of type 2 diabetes.
    Scheen AJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of cannabinoid receptors and glucose metabolism.
    Scheen AJ; Paquot N
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
    Kyrou I; Valsamakis G; Tsigos C
    Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
    Patti ME
    J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rimonabant: new data and emerging experience.
    Wright SM; Dikkers C; Aronne LJ
    Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoid system and cardio-metabolic risk.
    Loh KY; Kew ST
    Med J Malaysia; 2008 Oct; 63(4):348-50; quiz 351. PubMed ID: 19385504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.